Planning and management to control and eliminate HTLV-1 infection in Iran

Document Type : Commentary


1 Department of Neurology, Mashhad University of Medical Sciences, Mashhad, Iran

2 Department of Research, Faculty of Medicine, Mashhad University of medical sciences, Mashhad, Iran

3 Immunology Research Centre, Inflammation and Inflammatory Diseases Division, Mashhad University of Medical Sciences, Mashhad, Iran

4 Allergy Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran


Prevention and treatment of the Human T-cell leukemia virus, type 1 (HTLV-1) which was discovered nearly 40 years ago, still remain challenging. The reported high prevalence of HTLV-1 in some countries around the world triggered an open letter to the World Health Organization (WHO), urging action against HTLV-1 infection in 2018. This highlights the importance of virus elimination strategies to eradicate HTLV-1 infection. In Iran, we have documented our experiences with the virus in order to achieve and promote the possible ways to manage, control, and eliminate HTLV-1. Although there has been considerable progress apropos of HTLV-1, a series of additional challenges need to be tackled to control HTLV-1 infection in Iran. 


1. Martin F, Castro H, Gabriel C, Adonis A, Fedina A, Harrison L, et al. Ciclosporin A proof of concept study in patients with active, progressive HTLV-1 associated myelopathy/tropical spastic paraparesis. PLoS Negl Trop Dis 2012;6:e1675.
2. Hermine O, Ramos JC, Tobinai K. A review of new findings in adult T-cell leukemia-lymphoma: A focus on current and emerging treatment strategies. Adv Ther 2018;35:135-152.
3. Martin F, Tagaya Y, Gallo R. Time to eradicate HTLV-1: an open letter to WHO. Lancet 2018;391:1893-1894.
4. Nishijima T, Shimada S, Noda H, Miyake K. Towards the elimination of HTLV-1 infection in Japan. Lancet Infect Dis 2019;19:15-16.
5. Azarpazhooh MR, Hasanpour K, Ghanbari M, Rezaee SA, Mashkani B, Hedayati-Moghaddam MR, et al. Human T-lymphotropic virus type 1 prevalence in northeastern Iran, Sabzevar: an epidemiologic-based study and phylogenetic analysis. AIDS Res Hum Retroviruses 2012;28:1095-1101.
6. Rafatpanah H, Hedayati-moghaddam Mr, Fathimoghadam F, Bidkhori HR, Shamsian S, Ahmadi Ghezeldasht S, et al. High prevalence of HTLV-I infection in Mashhad, Northeast Iran: A population-based seroepidemiology survey. J Clin Virol 2011;52:172-176.
7. Karimi G, Zadsar M, Pourfathollah AA. Seroprevalence and geographical distribution of human T-lymphotropic virus type 1 among volunteer blood donors in endemic areas of Iran. Virol J 2017;14:14-28.
8. Hedayati-Moghaddam MR. A systematic review for estimation of HTLV-I infection in the blood donors of Iran. Iran J Basic Med Sci 2013; 16:196–201.
9. Kalavi Kh, Moradi A, Tabarraei A. Population-based seroprevalence of HTLV-I infection in Golestan province, South East of Caspian Sea. Iran J Basic Med Sci 2013;16:225-228.
10. Hoque DM, Kumari V, Ruseckaite R, Romero L, Evans SM. Impact of clinical registries on quality of patient care and health outcomes: protocol for a systematic review. BMJ Open 2016;6:e010654.
11. Rafatpanah H, Rezaee SAR, Etemadi M, Hosseini R, Khorram B, Afsahr L, et al. The impact of interferon-alpha treatment on clinical and immunovirological aspects of HTLV-1-associated myelopathy in northeast of Iran. J Neuroimmunol 2012;250:87-93.
12. Kchour G, Tarhini M, Kooshyar M-M, El Hajj H, Wattel E, Mahmoudi M, et al. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood 2009;113:6528-632.